Man Group
BCYC

Man Group’s Bicycle Therapeutics BCYC Stock Holding History

Man Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$294K Buy
63,305
+20,445
+48% +$117K ﹤0.01% 2216
2025
Q4 		$303K Buy
42,860
+1,969
+5% +$14.5K ﹤0.01% 2015
2025
Q3 		$316K Buy
40,891
+12,216
+43% +$92.2K ﹤0.01% 1988
2025
Q2 		$199K Buy
+28,675
New +$228K ﹤0.01% 2075
2024
Q1 		– Sell
-174,074
Closed -$3.15M – 2120
2023
Q4 		$3.15M Buy
+174,074
New +$2.88M 0.01% 1133
2022
Q2 		– Hold
0
– – – 1791

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Man Group's BCYC Position: Q1 2026 in Review

Man Group increased its Bicycle Therapeutics (BCYC) stake by 48% in Q1 2026, buying an estimated $117K and bringing the position to 63,305 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Man Group first reported a position in BCYC in Q4 2023 and has held it in 5 quarters since. The position peaked at $3.15M in Q4 2023. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Man Group held 63,305 shares of Bicycle Therapeutics worth $294K as of Q1 2026.
  • Man Group bought 20,445 Bicycle Therapeutics shares in Q1 2026, an estimated $117K.
  • Bicycle Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2216 holding.
  • Man Group first reported a position in Bicycle Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • Man Group's Bicycle Therapeutics position peaked at $3.15M in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.